Brokerages Set Enfusion, Inc. (NYSE:ENFN) Target Price at $9.33

Shares of Enfusion, Inc. (NYSE:ENFN) have been given a consensus recommendation of “Reduce” by the six analysts that are currently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $9.33.

A number of analysts have weighed in on ENFN shares. Morgan Stanley assumed coverage on Enfusion in a report on Friday, May 10th. They set an “overweight” rating and a $11.00 target price for the company. Bank of America raised their price objective on Enfusion from $8.00 to $9.00 and gave the company an “underperform” rating in a research report on Wednesday, March 13th.

Enfusion Trading Up 0.3 %

ENFN opened at $8.43 on Wednesday. The business’s fifty day simple moving average is $9.04 and its 200-day simple moving average is $9.03. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of 280.83, a PEG ratio of 1.98 and a beta of 0.92. Enfusion has a 12-month low of $7.52 and a 12-month high of $11.56.

Enfusion (NYSE:ENFN) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.05). Enfusion had a net margin of 1.40% and a return on equity of 6.60%. The business had revenue of $48.05 million during the quarter, compared to the consensus estimate of $47.67 million. During the same quarter in the prior year, the firm posted $0.04 EPS. On average, equities research analysts predict that Enfusion will post 0.09 EPS for the current year.

Insider Activity

In related news, Director Deirdre Somers sold 4,629 shares of the business’s stock in a transaction on Friday, June 14th. The stock was sold at an average price of $8.40, for a total transaction of $38,883.60. Following the transaction, the director now directly owns 43,312 shares in the company, valued at approximately $363,820.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other Enfusion news, insider Bronwen Bastone sold 10,539 shares of the firm’s stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $8.17, for a total value of $86,103.63. Following the completion of the transaction, the insider now owns 217,154 shares of the company’s stock, valued at $1,774,148.18. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Deirdre Somers sold 4,629 shares of Enfusion stock in a transaction on Friday, June 14th. The stock was sold at an average price of $8.40, for a total transaction of $38,883.60. Following the sale, the director now owns 43,312 shares of the company’s stock, valued at $363,820.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 36,318 shares of company stock worth $296,688. Insiders own 36.44% of the company’s stock.

Hedge Funds Weigh In On Enfusion

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ENFN. California State Teachers Retirement System increased its holdings in shares of Enfusion by 11.0% in the first quarter. California State Teachers Retirement System now owns 36,002 shares of the company’s stock valued at $333,000 after purchasing an additional 3,556 shares during the period. Price T Rowe Associates Inc. MD purchased a new stake in shares of Enfusion in the 1st quarter valued at $102,000. Quadrature Capital Ltd purchased a new stake in Enfusion in the first quarter valued at $109,000. Vanguard Group Inc. boosted its stake in shares of Enfusion by 1.4% in the first quarter. Vanguard Group Inc. now owns 3,653,189 shares of the company’s stock worth $33,792,000 after buying an additional 51,670 shares during the last quarter. Finally, Bleakley Financial Group LLC purchased a new stake in Enfusion in the 1st quarter worth approximately $176,000. Hedge funds and other institutional investors own 81.05% of the company’s stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.